What is Prosidyan?
Founded in 2009, Prosidyan is dedicated to developing advanced synthetic bioactive bone graft substitutes leveraging proprietary bioactive glass fiber technology. The company's product portfolio includes FDA-cleared innovations such as FIBERGRAFT BG Morsels, FIBERGRAFT BG Putty (enhanced with their proprietary OSSIGLIDE® carrier), and the FIBERGRAFT BG Matrix, which incorporates a type I collagen-based bioactive carrier. These offerings represent a significant advancement over traditional bone grafting materials, providing enhanced osteoconductivity and bioactivity for orthopedic applications.
How much funding has Prosidyan raised?
Prosidyan has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
What's next for Prosidyan?
With its recent substantial capital infusion, Prosidyan is strategically positioned for accelerated market penetration and product development. The company's focus on late-stage funding indicates a transition towards scaling operations, expanding commercial reach, and potentially exploring new therapeutic areas or product enhancements. This investment will likely support increased manufacturing capacity, broader clinical adoption, and further research into the therapeutic potential of its bioactive glass fiber technology, solidifying its market leadership in synthetic bone graft substitutes.
See full Prosidyan company page
